Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

orted more commonly in the placebo arm. During the study, one death in the everolimus arm occurred due to convulsion, though it was not considered related to the study drug by the investigator(1).

EXIST-2 enrolled 118 patients in the US, Germany, the Netherlands, Japan, the UK, Russia, Italy, Canada, Poland, Spain and France. This study is part of a Phase III trial program investigating everolimus in the various manifestations of TSC(1,10).

About everolimusIn the US, Afinitor® (everolimus) tablets is approved to treat patients with SEGA associated with TS who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown.

Afinitor is also approved in the US for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib and for the treatment of progressive neuroendocrine tumors of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease. The US Food and Drug Administration (FDA) determined that the safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumors have not been established.

In the US, everolimus is available from Novartis in different dosage strengths and for different uses in non-oncology patient populations under the trade name Zortress®. Everolimus is exclusively licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents.

Not all indications are available in every country. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. As an investigational compound, the safety and efficacy profile o
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy ... clinics opened in Memphis and ... added in Springfield on September 24 and ... to open October 22.  MinuteClinic is the largest and fastest growing ... . The Memphis -area clinics ...
(Date:9/19/2014)... 19, 2014 According to ... (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, ... & Rotary) & Geography - Global Trends & ... segments the lyophilization market on the basis of ... projections of the market size of each of ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Pressure ... today announced it has received and approved all ... HT48 instruments and has begun to manufacture the ... first instrument will be ready for shipment by ... built and released at a rate of about ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 The ... important partnership with the National Fire Protection Association ... The collaboration, formalized today in a Memorandum of ... Members, factories, workers and other stakeholders with information, ... help protect the health and safety of workers ...
(Date:9/19/2014)... to treat and cure disease is a hugely ... by the inability of doctors and scientists to effectively ... in patients without resorting to invasive procedures, like tissue ... the online journal Magnetic Resonance in Medicine , ... of Medicine, University of Pittsburgh and elsewhere describe the ...
(Date:9/19/2014)... 2014) - New research published today in the online ... could reach 6,800 in West Africa by the end ... enacted. , Arizona State University and Harvard University ... of rise in cases significantly increased in August in ... quarantine was put in place, indicating that the mass ...
(Date:9/19/2014)... Researchers at Jacksonville,s campus of Mayo Clinic have ... say contributes to both overproduction of toxic protein in ... well as loss of communication between neurons both ... study, in the online issue of Neuron ... defect with drugs "may rejuvenate or rescue this pathway," ...
Breaking Medicine News(10 mins):Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A better way to track emerging cell therapies using MRIs 2Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2
... Self-Funding,Healthcare Conference and Expo will provide employers and health ... both carriers and,brokers during a June 1-3, 2009 conference ... The conference is unique, as it is designed and ... Karrie Andes, Director of Human,Resources for Deffenbaugh Industries, ...
... (Nasdaq: DYNT ) today announced that a ... the SEC, gives the company until approximately June 28, ... bid rule."We are pleased that NASDAQ has further extended ... market environment," stated Kelvyn H. Cullimore Jr., chairman and ...
... tumors seen in mouse study , , MONDAY, Dec. 29 ... phosphates found in many natural and processed foods accelerated ... researchers report. , "Our study suggests that dietary regulation ... treatment as well as prevention," Myung-Haing Cho, lead author ...
... widespread media attention given to studies that have indicated ... new study shows just one-third of children who are ... pediatrician. The study, led by researchers at The ... Medicine in Cleveland, also stresses that this failure to ...
... Technology,Inc. ("Versus" or the "Company") announced revenues of ... compared to revenues of $5,566,000 for fiscal,year 2007. ... 31, 2008, were,$1,748,000 compared to revenues of $2,012,000 ... can vary significantly depending on the timing and,delivery ...
... MANHATTAN, KSThe Centers for Disease Control and Prevention and ... 30 minutes of moderate-intensity physical activity on most days ... optimal health. This recommendation is especially important for older ... requirement, yet are more at risk for chronic diseases ...
Cached Medicine News:Health News:Spending Too Much on Healthcare? This Employer-Designed Conference Will Inspire! 2Health News:NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance 2Health News:Food Phosphates Might Spur Lung Cancer 2Health News:Food Phosphates Might Spur Lung Cancer 3Health News:Can't chalk it up to 'baby fat' 2Health News:Versus Technology Announces Fiscal Year Results 2Health News:Versus Technology Announces Fiscal Year Results 3Health News:Versus Technology Announces Fiscal Year Results 4Health News:Versus Technology Announces Fiscal Year Results 5Health News:Versus Technology Announces Fiscal Year Results 6Health News:Versus Technology Announces Fiscal Year Results 7Health News:Another reason to get your hands dirty 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: